Mharrach Imane, Tadlaoui Kaoutar Anouar, Aqerrout Mouna, Laraqui Abdelilah, Ameur Ahmed, El Ghazzaly Anouar, Ennibi Khalid, Ennaji Moulay Mustapha
Laboratory of Virology, Oncology, Biosciences, Environment and New Energies, Faculty of Sciences and Techniques, Hassan II University of Casablanca, Casablanca 20650, Morocco.
Royal School of Military Health Service, Sequencing Unit, Laboratory of Virology, Center of Virology, Infectious and Tropical Diseases, Mohammed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat 10000, Morocco.
Mol Clin Oncol. 2025 Mar 11;22(5):40. doi: 10.3892/mco.2025.2835. eCollection 2025 May.
Prostate cancer (PCa) is globally the second most diagnosed malignancy in men, with >1.5 million new cases reported in 2020. Given the limitations of classical detection methods, the discovery of new predictive PCa biomarkers is critical. MicroRNAs (miRs), which are small, single-stranded, non-coding RNA molecules, have emerged as potential biomarkers for cancer diagnosis and prognosis. The present study aimed to evaluate the diagnostic value of miR-21 and miR-221 in PCa and their association with clinicopathological parameters. The expression of miR-21 and miR-221 was assessed using reverse transcription-quantitative PCR in 50 tumour and 50 control tissue samples. The results demonstrated that miR-21 and miR-221 were significantly upregulated in PCa tissues compared with that of the normal control tissues. Receiver operating characteristic curve analysis revealed that miR-21 had an area under the curve (AUC) of 0.90, with a sensitivity of 70% and a specificity of 96%. Similarly, miR-221 demonstrated an AUC of 0.89, with a sensitivity of 86% and a specificity of 78%. High expression of miR-21 and miR-221 was also demonstrated to be associated with higher Gleason scores and advanced tumour stages. The findings of the present study indicate the potential role of miR-21 and miR-221 as biomarkers in the diagnosis of PCa. However, further studies in non-invasive samples such as serum, blood and urine are needed to support the results of the present study.
前列腺癌（PCa）是全球男性中第二大最常被诊断出的恶性肿瘤，2020年报告的新病例超过150万例。鉴于传统检测方法的局限性，发现新的前列腺癌预测生物标志物至关重要。微小RNA（miRs）是小的单链非编码RNA分子，已成为癌症诊断和预后的潜在生物标志物。本研究旨在评估miR-21和miR-221在前列腺癌中的诊断价值及其与临床病理参数的关联。使用逆转录定量PCR评估了50个肿瘤组织和50个对照组织样本中miR-21和miR-221的表达。结果表明，与正常对照组织相比，miR-21和miR-221在前列腺癌组织中显著上调。受试者工作特征曲线分析显示，miR-21的曲线下面积（AUC）为0.90，灵敏度为70%，特异性为96%。同样，miR-221的AUC为0.89，灵敏度为86%，特异性为78%。miR-21和miR-221的高表达还与更高的Gleason评分和晚期肿瘤分期相关。本研究结果表明miR-21和miR-221作为生物标志物在前列腺癌诊断中的潜在作用。然而，需要对血清、血液和尿液等非侵入性样本进行进一步研究以支持本研究结果。
